Compare Stocks: JNJ, KVUE, NVO, and LLY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$253.50 -0.8%	$265.66	$184.66 ▼ $281.07	$611.18B	0.21	7.98 million shs	2.81 million shs
KVUE Kenvue	$18.81 -0.6%	$18.33	$14.02 ▼ $20.13	$36.12B	0.48	27.24 million shs	4.52 million shs
LLY Eli Lilly and Company	$1,248.54 -0.7%	$1,180.08	$793.82 ▼ $1,292.65	$1.18T	0.46	2.94 million shs	758,747 shs
NVO Novo Nordisk A/S	$38.43 -1.0%	$42.70	$35.12 ▼ $64.16	$171.66B	0.76	16.75 million shs	3.57 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	-2.19%	-5.35%	+2.70%	+32.22%
KVUE Kenvue	0.00%	+7.01%	+6.05%	-0.54%	+23.46%
LLY Eli Lilly and Company	0.00%	+6.83%	+9.15%	+9.69%	+56.56%
NVO Novo Nordisk A/S	0.00%	+0.39%	-10.31%	-21.84%	-28.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$253.50 -0.8%	$265.66	$184.66 ▼ $281.07	$611.18B	0.21	7.98 million shs	2.81 million shs
KVUE Kenvue	$18.81 -0.6%	$18.33	$14.02 ▼ $20.13	$36.12B	0.48	27.24 million shs	4.52 million shs
LLY Eli Lilly and Company	$1,248.54 -0.7%	$1,180.08	$793.82 ▼ $1,292.65	$1.18T	0.46	2.94 million shs	758,747 shs
NVO Novo Nordisk A/S	$38.43 -1.0%	$42.70	$35.12 ▼ $64.16	$171.66B	0.76	16.75 million shs	3.57 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	-2.19%	-5.35%	+2.70%	+32.22%
KVUE Kenvue	0.00%	+7.01%	+6.05%	-0.54%	+23.46%
LLY Eli Lilly and Company	0.00%	+6.83%	+9.15%	+9.69%	+56.56%
NVO Novo Nordisk A/S	0.00%	+0.39%	-10.31%	-21.84%	-28.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$274.87	8.43% Upside
KVUE Kenvue	2.00	Hold	$18.43	-2.00% Downside
LLY Eli Lilly and Company	2.86	Moderate Buy	$1,313.43	5.20% Upside
NVO Novo Nordisk A/S	2.00	Hold	$59.44	54.69% Upside

Current Analyst Ratings Breakdown

Latest JNJ, KVUE, NVO, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$275.00 ➝ $287.00
10/15/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B) ➝ Buy (B+)
10/15/2026	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$270.00
10/15/2026	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$294.00 ➝ $292.00
10/14/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$276.00 ➝ $272.00
10/14/2026	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$282.00 ➝ $275.00
10/14/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$270.00
10/14/2026	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform
10/14/2026	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$290.00 ➝ $280.00
10/12/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Market Perform	$47.00 ➝ $40.00
10/12/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$1,500.00

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$99.34B	6.15	$14.01 per share	18.10	$33.85 per share	7.49
KVUE Kenvue	$15.12B	2.39	$1.37 per share	13.71	$5.62 per share	3.35
LLY Eli Lilly and Company	$79.67B	14.75	$24.97 per share	50.01	$28.07 per share	44.48
NVO Novo Nordisk A/S	$46.80B	3.67	$4.64 per share	8.28	$6.58 per share	5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$6.60	38.43	21.25	2.53	16.20%	31.54%	13.00%	N/A
KVUE Kenvue	$1.47B	$0.87	21.61	15.29	1.73	10.76%	21.22%	8.37%	11/2/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	41.92	26.46	1.67	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	9.40	11.24	1.32	35.36%	58.61%	20.91%	11/4/2026 (Estimated)

Latest JNJ, KVUE, NVO, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	NVO Novo Nordisk A/S	$0.7420	N/A	N/A	N/A	$11.15 billion	N/A
11/2/2026	Q3 2026	KVUE Kenvue	$0.2915	N/A	N/A	N/A	$3.86 billion	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.65	N/A	N/A	N/A	$22.47 billion	N/A
10/13/2026	Q3 2026	JNJ Johnson & Johnson	$2.53	$2.59	+$0.06	$0.09	$25.38 billion	$25.40 billion
8/6/2026	Q2 2026	KVUE Kenvue	$0.3187	$0.31	-$0.0087	$0.24	$3.97 billion	$3.96 billion
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	2.11%	+5.25%	81.21%	64 Years
KVUE Kenvue	$0.84	4.47%	N/A	96.55%	1 Years
LLY Eli Lilly and Company	$6.92	0.55%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.82	2.13%	+21.74%	20.05%	N/A

Latest JNJ, KVUE, NVO, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/13/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.15%	11/24/2026	11/24/2026	12/8/2026
9/10/2026	KVUE Kenvue	quarterly	$0.21	4.75%	9/21/2026	9/21/2026	10/2/2026
7/29/2026	KVUE Kenvue	quarterly	$0.21	4.43%	8/12/2026	8/12/2026	8/26/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
KVUE Kenvue	0.67	1.01	0.71
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.55	0.87	0.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
KVUE Kenvue	97.64%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
KVUE Kenvue	1.59%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
KVUE Kenvue	22,000	1.92 billion	1.89 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

JNJ, KVUE, NVO, and LLY Headlines

Recent News About These Companies

3 hours ago | zacks.com

Novo Nordisk Girds for November 4 Update With Buyback Past 10.5 Billion DKK and EU Rivalry Sharpening

3 hours ago | ad-hoc-news.deA

Novo Nordisk A/S (NVO) Stock Analysis: A Strong Dividend Player with Potential Upside

3 hours ago | directorstalkinterviews.com

Novo Nordisk A/S - share repurchase programme

3 hours ago | finance.yahoo.com

Is Novo Nordisk (CPSE:NOVO B) Cheap After Lillys EMA Win Raised GLP 1 Pressure?

October 18 at 6:26 PM | finance.yahoo.com

Is Novo Nordisk (CPSE:NOVO B) Facing A Bigger Threat In Europe?

October 18 at 1:26 PM | finance.yahoo.com

Novo Nordisk A/S $NVO Stock Position Cut by Banque Pictet & Cie SA

October 18 at 3:51 AM | marketbeat.com

Novo Nordisk A/S

October 17 at 1:03 PM | 247wallst.com

Novo Nordisk's Pipeline Patience Wears Thin as US Headwinds Build

October 17 at 1:03 PM | ad-hoc-news.deA

UBS keeps DKK 332 target for Novo Nordisk stock

October 16 at 1:14 PM | ad-hoc-news.deA

Novo Nordisk's Irish Plant Buildout and Indian Growth Bet Offset FDA Setback

October 16 at 1:14 PM | ad-hoc-news.deA

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

October 16 at 11:32 AM | fool.com

novo nordisk a/s - NVO

October 16 at 8:13 AM | foxbusiness.com

Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today in India

October 16 at 8:13 AM | goodreturns.inG

119,545 Novo Nordisk A/S $NVO Shares Acquired by Cantor Fitzgerald Investment Advisors L.P.

October 16 at 7:03 AM | marketbeat.com

Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount

October 15, 2026 | foreignpolicyjournal.comF

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)

...

October 15, 2026 | marketbeat.com

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading

October 15, 2026 | finance.yahoo.com

Novo Nordisk's Buyback Clears 10.5 Billion DKK as FDA Delay Clouds Denecimig Launch

October 14, 2026 | ad-hoc-news.deA

NVO - Novo Nordisk A/S

October 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JNJ, KVUE, NVO, and LLY Company Descriptions

Johnson & Johnson NYSE:JNJ

$253.50 -2.06 (-0.80%)

As of 01:20 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue NYSE:KVUE

$18.80 -0.11 (-0.56%)

As of 01:20 PM Eastern

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Eli Lilly and Company NYSE:LLY

$1,248.54 -8.49 (-0.68%)

As of 01:20 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$38.42 -0.41 (-1.04%)

As of 01:20 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, KVUE, NVO, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, KVUE, NVO, and LLY Earnings

Compare Dividends

Latest JNJ, KVUE, NVO, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, KVUE, NVO, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, KVUE, NVO, and LLY Company Descriptions

Johnson & Johnson NYSE:JNJ

Kenvue NYSE:KVUE

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools